Age-related macular degeneration (AMD) is a neurodegenerative disease of the aging retina, in which patients experience severe vision loss. Therapies available to patients are limited and are only effective in a sub-population of patients. Future comprehensive clinical care depends on identifying new therapeutic targets and adopting a multi-therapeutic approach. With this goal in mind, this review examines the fundamental concepts underlying the development and progression of AMD and re-evaluates the pathogenic pathways associated with the disease, focusing on the impact of injury at the cellular level, with the understanding that critical assessment of the literature may help pave the way to identifying disease-relevant targets. During this process, we elaborate on responses of AMD vulnerable cells, including photoreceptors, retinal pigment epithelial cells, microglia, and choroidal endothelial cells, based on and studies, to select stressful agents, and discuss current therapeutic developments in the field, targeting different aspects of AMD pathobiology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868387 | PMC |
| http://dx.doi.org/10.3389/fcell.2020.612812 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD.
Eye (Lond)
January 2025
Department of Medicine-Ophthalmology, University of Udine, Udine, Italy.
Objective: To evaluate the impact of evolving treatment paradigms for neovascular age-related macular degeneration (nAMD) by comparing outcomes between two patient cohorts treated with different anti-vascular endothelial growth factor (anti-VEGF) regimens over a decade apart.
Methods: This retrospective cohort study included 200 treatment-naive nAMD patients divided into two cohorts. Cohort 1 (2009-2010) was treated with a pro re nata (PRN) regimen, involving three initial monthly injections followed by as-needed treatments based on monthly monitoring.
Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases.
Adv Drug Deliv Rev
January 2025
Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel; Department of Molecular Genetics, Weizmann Institute of Science, 76100, Rehovot, Israel.
Self-renewal capacity and potential to differentiate into almost any cell type of the human body makes pluripotent stem cells a valuable starting material for manufacturing of clinical grade cell therapies. Neurodegenerative diseases are characterized by gradual loss of structure or function of neurons, often leading to neuronal death. This results in gradual decline of cognitive, motor, and physiological functions due to the degeneration of the central nervous systems.
View Article and Find Full Text PDFRNA Methylation Homeostasis in Ocular Diseases: All Eyes on Me.
Prog Retin Eye Res
January 2025
Department of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, State Key Laboratory of Vision Health, China. Electronic address:
RNA methylation is a pivotal epigenetic modification that adjusts various aspects of RNA biology, including nuclear transport, stability, and the efficiency of translation for specific RNA candidates. The methylation of RNA involves the addition of methyl groups to specific bases and can occur at different sites, resulting in distinct forms, such as N6-methyladenosine (mA), N1-methyladenosine (mA), 5-methylcytosine (mC), and 7-methylguanosine (mG). Maintaining an optimal equilibrium of RNA methylation is crucial for fundamental cellular activities such as cell survival, proliferation, and migration.
View Article and Find Full Text PDFAgreement between Color, Fluorescein Angiography, and SD-OCT in the Detection of Macular Fibrosis in Neovascular AMD.
Am J Ophthalmol
January 2025
Centre for Public Health, Faculty of Medicine and Health Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom. Electronic address:
Purpose: Color imaging is the accepted reference standard for detection of macular fibrosis in neovascular age-macular degeneration. Other imaging modalities of fluorescein angiography (FA) and spectral domain optical coherence tomography (SD-OCT) are also used but no formal agreement studies exist. We evaluated the agreement between fibrosis on colour, FA and SD-OCT-detected hyperreflective material (HRM) and their clinical relevance.
View Article and Find Full Text PDFOptimal Timing of Photobiomodulation Therapy for Retinal Diseases: Leveraging Circadian Mitochondrial Rhythms.
Photobiomodul Photomed Laser Surg
January 2025
Rubens Siqueira Research Center, São Jose do Rio Preto, Brazil.
Age-related retinal degeneration is associated with mitochondrial dysfunction. Emerging evidence suggests that photobiomodulation therapy (PBMT) using near-infrared light may improve mitochondrial function and visual performance, but its efficacy is critically time-dependent. This article explores how daily biological rhythms and mitochondrial function interact, focusing on the potential of timed PMBT for age-related eye diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!